news
Spanish doctors advocate for long-acting injectable HIV prevention
Spanish internists are pushing for wider access to long-acting injectable pre-exposure prophylaxis (PrEP) to prevent HIV. The Spanish Society of Internal Medicine (SEMI) highlights the benefits of these antivirals for populations at higher risk. This move aims to expand options beyond daily pills, making prevention more accessible and adherence easier.
Spanish internists are pushing for wider access to long-acting injectable pre-exposure prophylaxis (PrEP) to prevent HIV. The Spanish Society of Internal Medicine (SEMI) highlights the benefits of these antivirals for populations at higher risk. This move aims to expand options beyond daily pills, making prevention more accessible and adherence easier.
The architecture take
I've been watching policy changes around GLP-1s and psychedelics, but HIV prevention getting the long-acting injectable treatment feels like a quiet but significant shift in how we approach health policy. It's not just about compliance anymore; it's about making prevention as frictionless as possible for populations that need it most. When a drug can be administered less frequently, say, every few months instead of daily, the adherence rates jump dramatically. This reduces the cognitive load, the daily reminder, the possibility of missing doses. That's a direct win for nervous system resilience. Expect to see more of these 'set it and forget it' pharmaceutical options gain traction, especially as public health organizations lean into proactive, rather than reactive, care models. It also pushes the conversation beyond pills and into broader treatment modalities.